Patient recruitment is now underway in a clinical trial of Newel Health’s digital therapeutic for Parkinson’s disease, which hopes to show it can enhance the efficacy of t
Aspen Neuroscience is adding a digital dimension to a study of its experimental cell therapy for Parkinson's disease, with the help of tech companies Emerald Innovations a
Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication.